Considerations for Preclinical Safety Assessment of Adeno-Associated Virus Gene Therapy Products
- 7 October 2018
- journal article
- conference paper
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 46 (8) , 1020-1027
Abstract
Progress in understanding the molecular bases of human health and disease in recent decades has flourished making it possible for the field of gene therapy (GT) to offer new possibilities for treating, and even curing, a plethora of medical conditions such as monogenic disorders and metabolic diseases. GT is a therapeutic intervention to genetically alter or modify living cells by means of gene delivery achieved using either viral vectors or nonviral vectors, with adeno-associated virus (AAV) vectors constituting market-share majority. Although GT is conceptually attractive, adverse and even fatal iatrogenic complications have marred the initial enthusiasm of clinical successes. The properties of investigational AAV-based GT may pose safety concerns unique from those of small molecule drugs and other macromolecular biologics, such as ectopic or unregulated expression of the transgene, long-term persistence, and off-target distribution. Herein, we discuss considerations in the design of a comprehensive preclinical safety program for AAV-based GT prior to administration in humans.Keywords
This publication has 25 references indexed in Scilit:
- Selection and evaluation of clinically relevant AAV variants in a xenograft liver modelNature, 2013
- Immune responses to AAV vectors: overcoming barriers to successful gene therapyBlood, 2013
- A largely random AAV integration profile after LPLD gene therapyNature Medicine, 2013
- The Committee for Advanced Therapies' of the European Medicines Agency Reflection Paper on Management of Clinical Risks Deriving from Insertional MutagenesisHuman Gene Therapy Clinical Development, 2013
- Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic InjectionMolecular Therapy, 2008
- AAV Vector Integration Sites in Mouse Hepatocellular CarcinomaScience, 2007
- Inadvertent Germline Transmission of AAV2 Vector: Findings in a Rabbit Model Correlate with Those in a Human Clinical TrialMolecular Therapy, 2006
- Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune responseNature Medicine, 2006
- Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspectiveMolecular Therapy, 2004
- Lack of Germline Transmission of Vector Sequences Following Systemic Administration of Recombinant AAV-2 Vector in MalesMolecular Therapy, 2001